Mahendra Deonarain
Imperial College London
PharmacokineticsCancerFusion proteinAntigenMolecular biologyCytotoxic T cellAntibodyNotch signaling pathwayChemistryEpitopeConjugateIn vitroImmunologyIn vivoDrugPhotodynamic therapyRecombinant DNACancer researchMonoclonal antibodyCancer stem cellBiochemistryPotencyMedicineBiology
Publications 63
#1Mahendra Deonarain (Imperial College London)H-Index: 19
#2Gokhan Yahioglu (Imperial College London)H-Index: 24
Introduction: Antibody-Drug Conjugates (ADCs) have undergone a recent resurgence with 5 product approvals over the last 2 years but for those close to the field, it’s been repeated cycles of setbac...
3 CitationsSource
#1Mahendra Deonarain (Imperial College London)H-Index: 19
#2Quinn XueH-Index: 1
The pharmacokinetic-pharmacodynamic relationship is extremely complex and tumour drug penetration is one key parameter influencing therapeutic efficacy. In the context of antibody-drug conjugates (ADCs), which has undergone many innovation cycles and witnessed many failures, this feature is being addressed by a number of alternative technologies. Immunoglobulin-based ADCs continue to dominate the industrial landscape, but smaller formats offer the promise of more-effective cytotoxic payload deli...
#1Mahendra DeonarainH-Index: 19
#2Gokhan YahiogluH-Index: 24
Last. Quinn XueH-Index: 1
view all 12 authors...
Antibody Drug Conjugates (ADCs) are failing due to 3 critical limitations: Low potency, ineffective solid-tumour penetration and poor tolerability. The industry is full of approaches where full-length Immunoglobulins have been engineered to carry defined numbers of payloads with higher-loadings of less potent payloads appearing to be well-tolerated. However, antibody fragments (e.g. single-chain Fcs-scFvs), which have many advantages including rapid tumour penetration, faster clearance, inexpens...
2 CitationsSource
#1Agamemnon A. Epenetos (St Bartholomew's Hospital)H-Index: 32
#2Marianna ProkopiH-Index: 3
Last. Andreas S. Anayiotos (CUT: Cyprus University of Technology)H-Index: 18
view all 7 authors...
e17601Background: Notch signalling is implicated in tumorigenesis prompting scientists to research and develop anti-Notch therapeutics. Drugging the Notch pathway has been a challenge due to severe...
With Antibody-Drug Conjugate strategies firmly focussed on the precise conjugation to the large protein Immunoglobulin-G format, it is easy to miss the more recent technological innovations in small-format drug conjugates. Here, the targeting ligand can be at 50–95% reduced in size, or even smaller if peptidic in nature. Antibody domains or alternative binding scaffolds, chemically-modified with ultra-potent cytotoxic payloads offer an alternative approach for oncology therapeutics, promising a ...
9 CitationsSource
#1Hayley Pye (UCL: University College London)H-Index: 9
#2Mohammed A. Butt (UCL: University College London)H-Index: 9
Last. Laurence LovatH-Index: 34
view all 21 authors...
// Hayley Pye 1, * , Mohammed Adil Butt 1, 2, * , Laura Funnell 1 , Halla W. Reinert 1 , Ignazio Puccio 1 , Saif U. Rehman Khan 1 , Savvas Saouros 3, 4 , Jared S. Marklew 3 , Ioanna Stamati 3 , Maryam Qurashi 1, 4 , Rehan Haidry 2 , Vinay Sehgal 1, 2 , Dahmane Oukrif 5 , Michael Gandy 1 , Hayley C. Whitaker 1 , Manuel Rodriguez-Justo 5 , Marco Novelli 5 , Rifat Hamoudi 1, 6 , Gokhan Yahioglu 3, 4 , Mahendra P. Deonarain 1, 3, 4 and Laurence B. Lovat 1, 2 1 Department for Tissue and Energy, Divis...
5 CitationsSource
#1Mohammed A. Butt (UCL: University College London)H-Index: 9
#2Hayley Pye (UCL: University College London)H-Index: 9
Last. Laurence LovatH-Index: 34
view all 16 authors...
// Mohammed Adil Butt 1, 2, * , Hayley Pye 1, * , Rehan J. Haidry 2 , Dahmane Oukrif 3 , Saif-U-Rehman Khan 1 , Ignazio Puccio 1 , Michael Gandy 1 , Halla W. Reinert 1 , Ellie Bloom 1 , Mohammed Rashid 4 , Gokhan Yahioglu 5, 6 , Mahendra P. Deonarain 1, 5, 6 , Rifat Hamoudi 1 , Manuel Rodriguez-Justo 3 , Marco R. Novelli 3 , Laurence B. Lovat 1, 2 1 Department for Tissue & Energy, University College London, London, UK 2 Upper Gastrointestinal Service, University College London Hospitals NHS Foun...
9 CitationsSource
#1Agamemnon A. Epenetos (St Bartholomew's Hospital)H-Index: 32
#2Marianna ProkopiH-Index: 3
Last. Mahendra Deonarain (Imperial College London)H-Index: 19
view all 8 authors...
e23186Background: The Notch pathway has been associated with cancer and is implicated in tumorigenesis and regulation of cell fate. This pathway is an attractive target for the development of novel...
#1Luisa De Sordi (UCL Eastman Dental Institute)H-Index: 1
#2M. Adil Butt (UCLH: University College Hospital)H-Index: 3
Last. Laurence Lovat (UCLH: University College Hospital)H-Index: 34
view all 13 authors...
BACKGROUND: Clostridium difficile is the leading cause of antibiotic-associated diarrhoea and pseudo membranous colitis in the developed world. The aim of this study was to explore whether Photodynamic Antimicrobial Chemotherapy (PACT) could be used as a novel approach to treating C. difficile infections. METHODS: PACT utilises the ability of light-activated photosensitisers (PS) to produce reactive oxygen species (ROS) such as free radical species and singlet oxygen, which are lethal to cells. ...
12 CitationsSource
Reference EPFL-ARTICLE-204084doi:10.1007/s10549-014-3174-5View record in Web of Science Record created on 2014-12-30, modified on 2017-12-10
1 CitationsSource